Fig. 3
Effects of luteolin in combination with cisplatin on expression of apoptosis related proteins. CAOV3/DDP cells were treated with various concentrations of luteolin or cisplatin or the combination of both for 48 h, and then the expression of Bax, Bcl-2 was assessed by qRT-PCR and western blotting. a Relative Bcl-2 mRNA expression was normalized to β-actin; b Bax and Bcl-2 protein expressions of cells treated with luteolin; c Bax and Bcl-2 protein expressions of cells treated with the combination of cisplatin and increasing doses of luteolin. * P < 0.05, ** P < 0.01, *** P < 0.001, vs. control; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. cisplatin. CDDP: cisplatin. CDDP combined with luteolin (50, 100 μM) indicated a synergistic inhibitory effect on the Bcl-2 expression of CAOV3/DDP cells (Q = 1.43 ± 0.16 and 1.50 ± 0.09, respectively, > 1, P < 0.01 and P < 0.001, respectively)